Research programme: small molecule therapeutics- Pliant Therapeutics
Latest Information Update: 28 Mar 2020
Price :
$50 *
At a glance
- Originator Pliant Therapeutics
- Class Antifibrotics; Small molecules
- Mechanism of Action Integrin alphavbeta1 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for preclinical development in Fibrosis in USA
- 07 Sep 2018 Pliant Therapeutics and Cleveland Clinic enter into a research collaboration agreement to discover disease targets for gastrointestinal fibrosis
- 18 Feb 2016 Preclinical trials in Fibrosis in USA (unspecified route)